Pivotal readout

Mazdutide Gains China Reimbursement

Innovent says mazdutide has been included in China's 2026 national reimbursement drug list for glycemic control in adults with type 2 diabetes, with the revised list effective January 1, 2027. The company cites DREAMS phase 3 trials showing glycemic and weight benefits, including a 48% composite response rate in DREAMS-3 versus 21% with semaglutide. In obesity studies, mazdutide was associated with weight reductions of 14.84% at 48 weeks in GLORY-1 and 20.1% at 60 weeks in GLORY-2.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Schematic animation of a mazdutide molecule switching on the GLP-1 receptor on one cell and the glucagon receptor on a liver cell, each sending a signal inside its cell.
Mazdutide: one molecule, two hormone receptors. Watch the mechanism animation on the mazdutide page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call